Nectar Lifesciences, a Rs 725 crore plus leading integrated pharma entity, has raised Rs 252 crore through preferential allotment of equity shares and Global Depository Receipts (GDR).

Valeant Pharmaceuticals International has entered into an agreement with Spear Pharmaceuticals, Inc. for rights to commercialize Refissa, a prescription-based topical tretinoin cream used to diminish fine wrinkles and fade irregular pigmentation due to sun damage.

Nectar Lifesciences, a Rs 725 crore plus leading integrated pharma entity, has raised Rs 252 crore through preferential allotment of equity shares and Global Depository Receipts (GDR).

Ahmedabad based Contract Research and Manufacturing Services (CRAMS) major Dishman Pharmaceuticals and Chemicals Ltd has entered into a strategic alliance with California based biotechnology firm Codexis, Inc. that will allow Dishman to use of Codexis' proprietary enzymatic biocatalysis technology to manufacture intermediates and active pharmaceutical intermediates (APIs).